PRELUDE THERAPEUTICS INC
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-13.9M | $-10.4M | $-19.7M | $-31.2M | $-32.1M | $-32.3M | $-34.7M | $-31.4M |
| Depreciation & Amortization | — | $391.0K | — | — | $435.0K | — | — | $426.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $2.0M | — | — | $3.8M | — | — | $5.5M |
| Net Cash from Operating Activities | $-15.6M | $-21.7M | $-19.1M | $-26.1M | $-34.2M | $-27.3M | $-23.1M | $-31.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $0 | $0 | $20.0K | $47.0K | $63.0K | $359.0K | $289.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $8.5M | — | — | $62.2M | — | — | $31.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $-314.0K | — | — | $-160.0K | — | — | $-14.0K |
| Net Change in Cash | — | $-13.5M | — | — | $27.8M | — | — | $-584.0K |
| Free Cash Flow | $-15.6M | $-21.7M | $-19.1M | $-26.1M | $-34.3M | $-27.4M | $-23.4M | $-32.1M |